Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 12:00 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
March 30, 2026 11:45 ET | Source: Carbios

Grâce à des avancées significatives dans le financement de son projet industriel en France, Carbios confirme son objectif de construction de l’usine de Longlaville.

Carbios confirme son objectif concernant le projet de construction de l’usine de Longlaville, dans le cadre d’un financement de projet, avec pour objectif un démarrage de production à horizon S1...
March 30, 2026 11:45 ET | Source: Carbios

Supported by significant progress in the financing of its industrial project in France, Carbios confirms its objective to build the Longlaville plant

Carbios confirms its objective for the Longlaville plant construction project, within a project financing framework and a target of starting production by H1 2028.Carbios has a solid cash position,...
March 30, 2026 09:28 ET | Source: BiomX

BiomX Adds Former Mossad Deputy to Advisory Board

NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board. Dr. Levi will...
March 30, 2026 08:45 ET | Source: Immix Biopharma, Inc.

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

– Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch –– Onboarded Chief Medical...
March 30, 2026 08:30 ET | Source: AP Biosciences

AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)

TAIPEI, Taiwan, March 30, 2026 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific...
March 30, 2026 08:30 ET | Source: Transcenta

Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform

PRINCETON, N.J. and SUZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in...
March 30, 2026 08:01 ET | Source: Vor Biopharma

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports...
March 30, 2026 08:00 ET | Source: Vor Biopharma

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first...
March 30, 2026 08:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal...